Approved Research This page provides a searchable list of all research protocols that have been reviewed and approved by the Uganda National Council for Science and Technology(UNCST).
Search By Approval Date:
Clear Filter Total: 5,697
Name Title Nationality Approval Date Expiry Date Field of Science/Classification Trial Type Research Type  
AKELLO REBECCA AGNESS
ID:
PREVALENCE, SEVERITY AND FACTORS ASSOCIATED WITH ANAEMIA AMONG WOMEN ADMITTED FOR DELIVERY AT TERM AT MBARARA REGIONAL REFERRAL HOSPITAL
REFNo: HS3067ES

3. To identify the factors associated with anaemia among women admitted for delivery at term at Mbarara Regional Referral Hospital,2. To describe the severity of anaemia among women admitted for delivery at term at Mbarara Regional Referral Hospital ,1. To determine the prevalence of anaemia among women admitted for delivery at term at Mbarara Regional Referral Hospital ,To determine the prevalence, severity and factors associated with anaemia among women admitted for delivery at term at Mbarara Regional Referral Hospital.,
 Uganda 2023-10-23 13:09:03 2026-10-23 Medical and Health Sciences Non-Clinical Trial Degree Award
Jackline  Akello
ID: UNCST-2023-R005827
 Sickle cell disease in pregnancy: Experiences in provision and access to care and adverse pregnancy outcomes at Mbale and Kawempe Referral Hospitals
REFNo: HS5315ES

4.To explore health providers experiences in providing care to pregnant women with SCD at Mbale and Kawempe referral hospitals. ,To explore experiences of pregnant women with SCD in accessing health care at Kawempe and Mbale referral Hospitals. ,2.To determine risk factors for adverse fetal outcomes among pregnant women with SCD at Mbale and Kawempe Referral Hospitals,To determine risk factors for adverse maternal outcomes among pregnant women with SCD at Mbale and Kawempe Referral Hospitals ,The general objective is to determine the adverse maternal and fetal outcomes associated with pregnancies complicated by SCD and explore experiences in access and provision of care at Mbale and Kawempe Referral Hospitals. ,
 Uganda 2025-01-10 11:54:49 2028-01-10 Medical and Health Sciences Non-Clinical Trial Degree Award
Dickens Akena Howard
ID: UNCST-2019-R000179
 Neuropsychiatric Genetics of African Populations - Psychosis (NeuroGAP-P)
REFNo: HS14ES

i) Expand knowledge of the genetic architecture of schizophrenia and bipolar disorder in Africa through large-scale sample collection, analysis and follow-up.\r\n\r\nii) Increase understanding of the genetics of African populations\r\n\r\niii) Enhance neuropsychiatric genetic research capacity in Africa through the training of scientists and support the development of locally led research programs\r\n
 Uganda 2016-11-01 2019-11-01 Medical and Health Sciences Non-degree Award
Dickens Akena Howard
ID: UNCST-2019-R000179
 Developing a peer support model for depression care in patients with diabetes mellitus, and testing it’s efficacy on patient outcomes; a randomized control trial.
REFNo: HS20ES

The main study objective will be developing a peer support model of depression care for patients with DM and testing its efficacy on clinical outcomes
 Uganda 2017-02-24 2020-02-24 Medical and Health Sciences Non-degree Award
Dickens Akena Howard
ID: UNCST-2019-R000179
 The effect of psycho-education on clinical outcomes among patients with a first episode psychosis in central Uganda - A pilot randomized control trial
REFNo: HS1026ES

The study objectives are to (a) Conduct formative work and develop a manual for delivering psycho-education messages by Village Health Team (VHTs) members to individuals with first episode psychosis (FEP) and their families in central Uganda. (b) Examine the efficacy of psycho-education on symptom severity, stigma and retention in care. (c) Document feasibility and acceptability of implementing this intervention as well as barriers to its implementation
Uganda 2021-03-12 2024-03-12 Medical and Health Sciences Non-degree Award
Dickens Akena Howard
ID: UNCST-2019-R000179
 Integration of mental health care in communities affected by the COVID-19 pandemic - A cluster randomized trial of 24 villages in central Uganda
REFNo: HS1009ES

Our objectives will include: (a) Documenting MHL, PD, MDD, GAD, PTSD and SUD levels in the study population, (b) Determining the effectiveness of a psycho-education intervention delivered by village health team (VHT) members on study outcomes, (c) Determining the cost and cost effectiveness of delivering a psycho-education intervention, and (d) linking individuals in need of mental health care with the MOH psychosocial teams.
Uganda 2020-12-15 2023-12-15 Medical and Health Sciences Non-degree Award
Dickens Akena Howard
ID: UNCST-2019-R000179
 Genetics of Post-Traumatic Stress Disorders (PTSD) in African Ancestry Populations
REFNo: HS3156ES

(i) Expand knowledge of the genetic architecture of PTSD in the African continent through large-scale sample collection and analysis, (ii) Increase understanding of the high burden of trauma and PTSD faced by African populations and (iii) Enhance neuropsychiatric genetic research capacity in Uganda through the training of scientists and support the development of locally led research programs


 Uganda 2023-09-19 8:11:56 2026-09-19 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Dickens Akena Howard
ID: UNCST-2019-R000179
 NeuroGAP follow up study on Anhedonia, OCD, Discrimination, and Suicidality
REFNo: HS3158ES

1.Characterize anhedonia, OCD, stigma, and suicidality using diagnoses and item-level data collected across the NeuroGAP samples. 2. Generate high-quality harmonized phenotype data across psychiatric conditions in the study population, and 3. Conduct genetic analyses aimed at identifying genes linked to anhedonia, OCD, stigma and suicidality in the NeuroGAP-Psychosis the Ugandan populations, develop population-valid polygenic risk scores and contribute data to global meta-analyses aimed at identifying genes for these psychiatric conditions in African and trans-ethnic populations.
 Uganda 2023-09-08 14:00:44 2026-09-08 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Dickens Akena Howard
ID: UNCST-2019-R000179
 Cultural adaptation of the coordinated specialty care (NAVIGATE) in Uganda
REFNo: HS6280ES

Study objective: The study objectives will include

Objective 1. Culturally adapting and locally contextualizing NAVIGATE into a CSC manual (NAVIGATE-UG) for use in Uganda.

Objective 2: Documenting the feasibility and acceptability of using the adapted NAVIGATE-UG manual

Uganda 2025-08-18 13:24:11 2028-08-18 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Dickens Akena Howard
ID: UNCST-2019-R000179
 Neuropsychiatric Genetics of African Populations - Psychosis, II NeuroGAP-Psychosis II
REFNo: HS6452ES

i). Expand knowledge of the genetic architecture of schizophrenia and bipolar disorder in the African continent
through large-scale sample collection and analysis in Uganda
ii) Increase understanding of the genetics of African populations, through various methods for biospecimen
collection
iii) Enhance neuropsychiatric genetic research capacity in Africa through the training of scientists and supporting
the development of locally-led research programs
 Uganda 2025-08-27 14:38:09 2028-08-27 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Afiz Kibuuka Kibuuka
ID: UNCST-2021-R012755
 A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease
REFNo: HS1150ES

Objectives:
Primary Objectives
• To evaluate the fetal hemoglobin (HbF) response to IMR-687 versus placebo
• To evaluate the safety of IMR-687 versus placebo Seconduy Efficacy Objectives
• To evaluate the effect of IMR-687 versus placebo on HbF-associated biomarkers
• To evaluate the effect ofIMR-687 versus placebo on indices of red cell hemolysis
• To evaluate the effect ofIMR-687 versus placebo on indices of white blood cell (WBC) adhesion
To evaluate the effect of IMR-687 versus placebo on the incidence of vaso-occlusive crises (vocs)
• To evaluate the effect of IMR-687 versus placebo on quality of life measures Pharmacokinetic•Óbjectives
• To evaluate the PK ofIMR-687 and any major circulating metabolites
Exploratory Efficacy Objectives
To evaluate the effect of IMR-687 versus placebo on changes in red blood cell (RBC) characteristics and total Hb e To evaluate the effect of IMR-687 versus placebo on renal function
• To evaluate the effect of IMR-687 versus placebo on indices associated with cardiovascular pathophysiology and ischemic stroke risk

 Uganda 2021-02-11 2024-02-11 Medical and Health Sciences Non-degree Award
Afiz Kibuuka Kibuuka
ID: UNCST-2021-R012755
 A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19
REFNo: HS2642ES

The main intent of the study is to evaluate the efficacy of S-217622 vs. placebo. The study will be conducted in the setting of the locally available standard-of-care COVID-19 treatment. High-risk and low-risk participants will be analyzed together for the primary analysis and separately for secondary analyses. The following primary, secondary, and exploratory objectives will be addressed in the modified intent-to-treat (mITT) population, except for the safety analyses, which will be analyzed in the Safety population, and pharmacokinetic (PK) analyses, which will be analyzed in the PK population.
 Uganda 2023-02-06 17:17:04 2026-02-06 Medical and Health Sciences Clinical Trial Non-degree Award
Afiz Kibuuka Kibuuka
ID: UNCST-2021-R012755
 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises
REFNo: HS5365ES

To compare the efficacy of 5 mg/kg of crizanlizumab versus placebo, with or without hydroxyurea/hydroxycarbamide, on the annualized rate of VOCs* that are healthcare professional (HCP)-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) over the planned 52-week treatment period in SCD patients aged 12 years and older with a history of frequent VOCs (4-12 events in 12 months prior to the screening visit).
To compare the efficacy of 5 mg/kg of crizanlizumab versus placebo, with or without hydroxyurea/hydroxycarbamide, on the annualized rate of all VOCs including VOCs that are HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) and VOCs that are self-managed without recommendations from HCP during the event over the planned 52 week treatment period in SCD patients aged 12 years and older with a history of frequent VOCs (4-12 events in the 12 months prior to the Screeening visit
To evaluate the annualized rate of VOCs by type of management between treatment arms over the planned 52-week treatment period: • VOCs that are HCP-managed at a health care facility • VOCs that are HCP-managed via remote consultation • VOCs that are self-managed without recommendations from HCP during the event • VOCs that are HCP-managed via remote consultation or self-managed without recommendations from HCP during the event
To evaluate the time to first VOC that is HCP managed (including VOCs leading to management at a health care facility or those managed via remote consultation) between treatment arms over the planned 52-week treatment period.
To evaluate the proportion of participants free from VOCs that are HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) between treatment arms over the planned 52-week treatment period.
 Uganda 2024-12-23 11:34:49 2027-12-23 Medical and Health Sciences Clinical Trial Non-degree Award
Agnes Kiragga
ID:
Tracing non-rEtained HIV PoSitivE Pregnant Women enrolled in Option B+ and ascertaining their BabIeS outcomes (sTEPWISe)
REFNo: HS35ES

Specific Aim 1: Trace women, initiated ART under option B+ who disengaged from care and assess reasons for disengagement, as well as obtain corrected estimates of retention by evaluating the proportion of mothers who have re-engaged or died.\r\nSpecific Aim 2: Assess and compare HIV transmission rates among infants born to retained and disengaged mothers. \r\nSub-aim 2.1. Perform HIV DNA PCR testing on the infants of disengaged women \r\nSub-aim 2.2 Obtain HIV status data on infants of retained women from existing medical records, or by providing HIV DNA-PCR testing for untested-infants or those whose test was performed within the previous month.\r\nSpecific Aim 3: To measure efavirenz (EFV) levels in the blood collected from all re-engaged and a matched sample of retained women. \r\nSpecific Aim 4: To perform genotypic testing among retained and disengaged women with virologic failure defined as viral load ≥1,000 copies/ml in order to describe mutations that are known to confer drug resistance. \r\n
 Uganda 2017-05-05 2020-05-05 Medical and Health Sciences Non-degree Award
Agnes Kiragga
ID:
Men at Gaming Centers: Point of Care HIV and STI Testing
REFNo: HS70ES

• To test the acceptability and feasibility of same day testing of HIV and syphilis testing, test result notification, prevalence of HIV and syphilis, and proportion linked to care among men attending at gaming/betting centers • To identify the proportion of men involved in other self-reported risky behaviors such as hazardous alcohol intake, illicit drug use, having sex with men and having multiple sexual partners, • To test the diagnostic performance of the ChemBio duo HIV-syphilis point of care test.
Uganda 2017-05-30 2020-05-30 Medical and Health Sciences Non-degree Award
Agnes Kiragga
ID:
Locating disengaged HIV positive women on Option B+ and ascertainment of outcomes among their infants
REFNo: HS175ES

1. To describe the pregnancy outcomes and HIV care status among women (and their exposed infants) who initiate Option B+ 2. To correct 6 week and 18 month estimates of MTCT through tracing of a random sample of HIV positive women who initiated Option B+ during pregnancy and disengaged from care. 3. To identify factors associated with HIV sero-positivity among infants born to women initiated on Option B+. 4. To establish the frequency of Multiclass Resistance among HIV positive infants born to women initiated on Option B+ 5. To estimate the proportion of disengaged women with viral failure and correct estimates of viral suppression (3 rd UN 90 goal) in the facilities.
 Uganda 2018-04-04 2021-04-04 Medical and Health Sciences Non-degree Award
Agnes Kiragga
ID:
A Pilot Test of a Technology-delivered HIV Self-Testing Intervention in Kampala, Uganda
REFNo: HS307ES

1) An established 24-hour call-in center staffed by medical providers who will deliver accurate HIV/STI information, perform pre- and post-test counselling, assist with conducting HIVST and interpreting the HIVST results, and referral and linkage to appropriate post-test prevention and treatment care; and 2) The use of SMS and social media streams – specifically private Facebook and Twitter messages - to “push” theoretically-grounded messages that promote HIVST and provide additional private communication routes between participants and medical provider research staff. The study aims are: Aim 1: Develop HIVST messages and finalize study procedures and materials with input from a Community Advisory Board (CAB), and beta test the intervention with 6 sexually active Ugandan adults (18-49 years old; 50% female). Aim 2: Using a pre-post design, assess the feasibility, acceptability and preliminary impact of the HIVST intervention developed in Aim 1 for Ugandan adults (n=100; 70% 18-24 years old, 30% 25-49 years old; 50% female). Feasibility will be assessed by whether enrollment targets are reached and the proportion of completed 1- and 3-month follow-ups calls. Acceptability items will be gathered at 1- and 3-month assessments. Preliminary impact will be determined by the percentage of participants who perform HIVST in the 3 months after enrollment. Aim 3: Analyze process indicators of the overall use of the HIVST intervention, including the number of HIVST kits requested, the volume of callers requesting HIVST during the study period, the number of persons calling for assistance with self-testing procedures, the number of post-test counseling calls received, and the number of persons linked to follow-up prevention and care services.
Uganda 2019-02-26 2022-02-26 Medical and Health Sciences Non-degree Award
Agnes Kiragga
ID:
Reproductive Health Empowerment through Telehealth
REFNo: HS425ES

1-With input from a Community Advisory Board develop a user-centered mobile-based reproductive health content targeted for men through SMS, interactive voice response.
2-Assess the feasibility and acceptability of the Men’s Telehealth Information Package (mTIP) on uptake of family planning and reproductive health services.
3-Assess the men’s knowledge and attitudes towards family planning following receipt of the Men’s Telehealth Information Package (mTIP)
4-Assess uptake of and attitudes towards FP and couple communication among women whose spouses received the Men’s Telehealth Information Package (mTIP) intervention.

 Uganda 2019-08-06 2022-08-06 Medical and Health Sciences Non-degree Award
Agnes Kiragga
ID:
Community Pharmacies for Assessing STI Prevalence using Point of Care diagnostics study (COPHAS)
REFNo: HS1274ES

Aim 1: To estimate the prevalence of curable STIs and HIV among persons accessing health services at community pharmacies in Kampala and Wakiso Districts.

Aim 2: To determine the feasibility and uptake of pharmacy-based specimen collection and POC testing for curable STIs and HIV among persons seeking health care services at community pharmacies in Kampala and Wakiso Districts. Uptake will be measured among the three groups of persons i.e. Persons seeking EC (group 1), clients with STI symptoms (group 2) and persons without STI symptoms (group 3)
Secondary quantitative aims:
Aim 3: To determine treatment completion among persons diagnosed with an STI at the community pharmacies in Kampala and Wakiso Districts.

Aim 4: To determine linkage to care and ART initiation among newly diagnosed HIV positive persons at the community pharmacies in Kampala and Wakiso Districts.

Aim 5: To determine the baseline and 3-month knowledge about STI and STI treatment guidelines, and principles of antimicrobial stewardship of pharmacy staff. In addition, to assess the acceptability of POC STI diagnostics collocated with the pharmacy, to pharmacy owners and staff.

Qualitative aims
Aim 6: To assess the acceptability and client satisfaction of STI and HIV testing at community pharmacies in Kampala and Wakiso Districts.

Partner notification sub-study
Aim 7: To determine the effect of technology-supported partner notification and treatment initiation using Call for LifeTM technology among persons diagnosed with an STI or HIV at community pharmacies.


 Uganda 2021-03-26 2024-03-26 Medical and Health Sciences Non-degree Award
Agnes Kiragga
ID:
Piloting a HIV Risk assessment application to increase awareness and uptake of HIV prevention services among young adults in Uganda. (SIDARISK)
REFNo: HS1293ES

• To assess the extent of high-risk sexual behavior and related practices among young adults using a web-based individualized HIV risk platform (SIDARISK)
• To establish the feasibility of using an existing telehealth platform for the referral and linkage to HIV/STI testing and prevention services following risk assessment by the SIDARISK application.
• To understand acceptability of the SIDARISK application for HIV risk assessment among young adults in Uganda
• To establish the feasibility of using a telehealth platform for provision of information on HIV risk reduction and linkage to HIV and PrEP services following using of the SIDARISK application

 Uganda 2021-03-18 2024-03-18 Medical and Health Sciences Non-degree Award
View Sort By:

"A prosperous Science and Technology Led Ugandan Society."

NRIMS